Pre-Treatment and Post-Treatment Anxiety, Depression, Sleep and Sexual Function Levels in Patients with Breast Cancer

İzci, Filiz; Özdem, Gözdem; İlgün, Ahmet Serkan; Agacayak, Filiz; Duymaz, Tomris; Erdoğan, Zeynep; Alço, Gül; Elbüken, Filiz; Ozturk, Alper; Ordu, Çetın; Ateşal, Kübra Ceren; Doğan, Özge İpek; Aktepe, Fatma; Özmen, Vahit

doi:10.5152/ejbh.2020.5259

Cited by 12 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age of women ranged from 25 to 69 years [1,2,9,[15][16][17][18][19][20][21][22][23][24][25][26][27]; most were married [1,2,9,18,20,21,24,25,27] and lived in the United States, Germany, or Belgium [9,[15][16][17][18]20,21,23,25]. The types of cancers analyzed in women with sexual dysfunctions were breast, cervical, endometrial, ovarian, vulvar, and gynecological [1,2,9,[15][16][17][18][19][20][21][22][23][24][25][26][27]. Additionally, women with cancer were treated with surge...…”

Section: Resultsmentioning

confidence: 99%

“…The types of cancers analyzed in women with sexual dysfunctions were breast, cervical, endometrial, ovarian, vulvar, and gynecological [1,2,9,[15][16][17][18][19][20][21][22][23][24][25][26][27]. Additionally, women with cancer were treated with surgery, chemotherapy, radiotherapy, or hormonal therapy [1,2,9,[15][16][17][18][19][20][21][22][23][24][25][26][27]. The follow-up time ranged from six months to five years [16][17][18][19][20][21][22][23]25].…”

Section: Resultsmentioning

confidence: 99%

“…The increase of survivors of cancer in recent decades has drawn attention to factors previously neglected in the health of these individuals, such as sexual function. Specifically, the female sexual function is highly impacted by health-related events, such as cancer, triggering sexual dysfunctions and reducing quality of life [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Cancer diagnosis and treatment may also cause suffering in women, who are usually vulnerable [8]. Most women with breast cancer have negative feelings and psychopathological, biological, and social symptoms, such as denial, anger, fear, fatigue, and mood, sleep, and sexual disorders [2]. Moreover, cancer treatment involves surgical interventions, neoadjuvant chemotherapy, anti-hormonal therapy, radiation, or targeted therapies, which may result in psychosocial effects and sexual dysfunctions [9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies

Guedes

Santana

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background: Several factors affect sexual function, including cancer development and treatment. This study summarized the risk of women with cancer of developing sexual dysfunctions. Methods: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched the EMBASE, PubMed, LILACS, SciELO, CINAHL, Scopus, and Web of Science databases using the descriptors cancer, neoplasms, sexual dysfunction, sexual function, and women. The Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies assessed the quality of studies. Results: Sixteen studies were included in this review. Women with cancer presented sexual dysfunctions in 14 out of 16 included studies. The incidence of sexual dysfunctions ranged from 30% to 80%, while the risk of developing sexual dysfunction increased 2.7- and 3.5-fold in women with cervical and breast cancer, respectively. Conclusion: Different cancer treatments increase the risk of developing sexual dysfunction in women, especially desire, arousal, and orgasm, leading to biopsychosocial changes in the health of this population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies

Guedes

Santana

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…7 However, psychological problems for this duration have been measured less, with the exception of a few longitudinal studies focusing on anxiety and depression. The results of those studies showed that symptoms of anxiety and depression were at high levels before cancer treatment, then either slightly declined 8,9 or increased. 10 Trajectory research found that 9% of patients were consistently anxious and depressed from pre-chemotherapy to 12 months post-chemotherapy.…”

mentioning

confidence: 99%

Perceived stress, anxiety, and depression in treatment‐naïve women with breast cancer: a case‐control study

Gao

Yang

et al. 2020

Psycho-Oncology

View full text Add to dashboard Cite

Objective Women with breast cancer face elevated risk for psychological problems. We aimed to examine to what extent treatment‐naïve women with breast cancer are at higher risk for perceived stress and symptoms of anxiety and depression, compared with matched women with benign breast disease and healthy women, and explore the contribution of perceived stress in the association between breast cancer and symptoms of anxiety and depression. Methods The study included 360 women (120 per group). Perceived stress and symptoms of anxiety and depression were assessed using self‐report questionnaires. We conducted linear and logistic regressions to assess increased risk and mediation analyses to test the role of perceived stress. Results After adjusting for potential confounders, perceived stress in women with breast cancer was 0.71 and 1.58 points higher than in patients with benign breast disease (p = 0.029) and healthy controls (p < 0.001), respectively; they were 1.85–2.44 times more likely to experience anxiety than either control group (p< 0.05) and 3.57 times more likely to experience depression than healthy controls (p < 0.001). The indirect effect of perceived stress between breast cancer and anxiety and depressive symptoms was 0.19–0.47 (p < 0.05). Conclusions This study demonstrates the high risk of perceived stress and symptoms of anxiety and depression in treatment‐naïve patients with breast cancer, and the association between breast cancer and increased anxiety and depressive symptoms through elevated perceived stress. It underscores the need to assess psychological status in pretreatment period and conduct stress‐targeted prehabilitation interventions.

show abstract

Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study

Ceylan

Metin

2021

Support Care Cancer

View full text Add to dashboard Cite

Background Paclitaxel regimen which is widely used in clinical treatment causes many negative physical and psychological consequences on women with breast cancer (BC). This longitudinal study firstly aimed to investigate symptom status, body perception changes, and the risk of anxiety and depression in BC patients receiving during paclitaxel regimen. Materials and methods This descriptive and prospective study was conducted with 84 BC patients receiving paclitaxel regimen. “Chemotherapy Symptom Assessment Scale (C-SAS),” “Body Perception Scale (BPS),” and “Hospital Anxiety and Depression Scale (HADS)” were applied at five time points (T 1 , before the first Paclitaxel infusion; T 2 , at the end of first cycle; T 3 , at the end of fourth cycle; T 4 , at the end of eighth cycle; T 5 , at the end of twelfth cycle). Data was analyzed using descriptive statistics, Cochrane Q, and linear mix model regression analysis. Results The frequency of needling and numbness in hands and feet, pain, and skin or nail changes significantly increased in the subsequent assessment points (T 2 , T 3 , T 4 , and T 5 ) compared to the initial assessment (T 1 ) ( p < 0.05). The mean scores of BPS significantly decreased at T 2 , T 4 , and T 5 compared to T 1 ( F = 8.152, p < 0.001). The mean scores of the anxiety subscale of the HADS scale decreased at the T 3 , T 4 , and T 5 compared to T 1 ( F = 6.865, p < 0.001), and the mean scores of the depression subscale significantly increased at the T 5 compared to T 1 ( F = 3.708, p = 0.006). Conclusions The oncology nurse should comprehensively evaluate the patients who scheduled to receive paclitaxel treatment, and provide counseling to the patients during these specific weeks. Better management of the symptoms that increase with the paclitaxel regimen with repeated interviews under the supervision of the nurse will also prevent the deterioration of body perception. In addition, since the risk of depression increases over time in patients receiving paclitaxel, nurses should periodically screen the risk of depression, and timely consult the patients for the appropriate support.

show abstract

Pre-Treatment and Post-Treatment Anxiety, Depression, Sleep and Sexual Function Levels in Patients with Breast Cancer

Cited by 12 publications

References 21 publications

Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies

Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies

Perceived stress, anxiety, and depression in treatment‐naïve women with breast cancer: a case‐control study

Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study

Contact Info

Product

Resources

About